Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8971 to 8985 of 8990 results

  1. Risdiplam not recommend for treating spinal muscular atrophy

    NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).

  2. NICE provides access to new treatment option for advanced breast cancer

    NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).

  3. People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy

    Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).

  4. New treatment for cardiovascular disease could benefit millions

    Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.

  5. Updated guideline recommends more treatment choices for menopause symptoms

    New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).

  6. NICE's positive recommendations for lung cancer treatments

    Home News Podcasts NICE's positive recommendations for lung cancer treatments Podcasts 20 January 2025 Listen About this episode We're joined

  7. Avelumab not recommended as a maintenance treatment of urothelial cancer

    NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.

  8. Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia

    Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.

  9. Patient safety and surgical innovation – why new isn't always better

    Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.

  10. New option for adult leukaemia patients as we recommend treatment

    Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.

  11. New life-changing treatment option recommended for type of rare epilepsy

    This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.

  12. Learn more about the NICE and NHS England MedTech Pathway consultation

    Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode

  13. Endometriosis - learn more about NICE's guideline for this chronic condition

    Home News Podcasts Endometriosis - learn more about NICE's guideline for this chronic condition Podcasts 25 March 2025 Listen About this episode

  14. Children and young people need accurate, accessible information about their healthcare

    New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.

  15. Children and young people set to benefit from new treatment for peanut allergy

    Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.